Payers, politicians and some regulators have been balking at the $84,000 price tag on Gilead's hepatitis C treatment Sovaldi ever since it hit the market in January. Now two top member of Congress are demanding that the company appear at a congressional hearing to explain the product's high price.
written on 20.06.2014